Quidelortho Corporation · NASDAQ:QDEL

Quidelortho — Quidel — Raymond James 41st Annual Institutional Investors Conference (March 2020)

15 slides from Quidelortho's conference presentation, Mar 3, 2020

  1. Slide 1: Investor Presentation Q1 2020

    INVESTOR PRESENTATION Q1 2020

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actu

  3. Slide 3: Quidel is committed to delivering strong performance by investing in growth and innovation

    Quidel is committed to delivering strong performance by investing in growth and innovation. 2009 - Present Revenues Over 25 FDA clearances $500.0 Acquired Triage and BNP Submitted over 30 510(k) and expanded product Businesses from Alere packages to the FDA claims, 4 CLIA waiver designations Launche

  4. Slide 4: Quidel sells products across the globe through the Quidel Network

    Quidel sells products across the globe through the Quidel Network - a broad channel mix composed of direct account managers and distribution partners. BC-BNP, BC-BNP, Quidel, 24% 15% Quidel, 52% 33% Canada EMEA Triage, $8 M $58 M 42% Triage, 1% 11% 33% BC-BNP, Quidel, 10% 43% China BC-BNP, 20% $68 M

  5. Slide 5: Our Cardiac acquisition has unlocked new markets

    Our Cardiac acquisition has unlocked new markets. Quidel Markets Non-Quidel Markets New QDEL Markets $Bn $Bn Global In Vitro Diagnostic Reagent Sales 8 Global Professional POC Test Sales * 80 Other 70 7 POC, Drugs of Abuse Professional/Hospital 60 POC - Consumer 6 Fecal occult blood Hematology Blood

  6. Slide 6: Active projects represent $1.7B in addressable market opportunity

    Active projects represent $1.7B in addressable market opportunity. Global Markets QDEL’s Opportunity Active / Near-term Projects $3,280 $1,734 Market Size Estimated Platform Product Geography (in millions) Addressable Strep 98 US $150 - $225 100% Vitamin D Europe $100 10% Inf Dis $1,165 Sofia $610 T

  7. Slide 7: Quidel's Main Objectives over 3-5 years

    Quidel's 3 Main Objectives over 3-5 years Leverage Assets Fully: Play a meaningful role in the Deploy capital wisely - Sofia MDx space: - Global Infrastructure - Solana - R&D Expertise - Savanna 7 Copyright © 2020 Quidel Corporation. All rights reserved.

  8. Slide 8: Influenza and Strep A

    Influenza and Strep A U.S. Influenza Test Data from Virena U.S. Strep A Test Data from Virena 8 Copyright © 2020 Quidel Corporation. All rights reserved.

  9. Slide 9: Our Instrumented Immunoassay systems have become flagship products

    Our Instrumented Immunoassay systems have become flagship products, combining quality, high sensitivity, low cost and fast diagnosis. Rapid Immunoassay Cardiac Immunoassay FDA–Cleared, CLIA–Waived FDA–Cleared, CLIA–Waived FDA–Cleared Sofia® Immunoassay platform is the next Sofia® 2, at a fraction of

  10. Slide 10: Our innovative molecular diagnostics products are designed to meet various customer needs

    Our innovative molecular diagnostics products are designed to meet the various needs of the customer in any POC setting. Molecular FDA–Cleared, FDA–Cleared, FDA–Cleared, In Development Mod–Complex Mod–Complex Highly–Complex AmpliVue®, a non-instrumented, Solana®, our first instrumented Lyra®, our Re

  11. Slide 11: Our company structure will evolve to better support growth

    Our company structure will evolve to better support growth in our key businesses Cardiometabolic Infectious Disease Other Create the Right Products Product Management R&D Manufacturing/ Operations Excellence Channel Sales & Marketing North America / China / RoW Customer Fulfillment (CS, TS, Distribu

  12. Slide 12: Quidel has aggressively reduced its leverage

    Quidel has aggressively reduced its leverage, which better positions the company for additional M&A opportunities. Transaction Date Debt Type Current Actions October 6, 2017 Re-paid $154 million through Convertible Bond Debt $167 million $13 million opportunistic convertible bond exchange transactio

  13. Slide 13: Maximizing Shareholder Value

    Maximizing Shareholder Value: Achieve 7% or higher in annual revenue growth through new product introductions Invest in the development and commercialization of new products driving gross margins to 65% Leverage operational efficiency driving EBITDA margins to 35% Maximize cash flow from the core bu

  14. Slide 14: Our M&A Strategy: What we're looking for

    Our M&A Strategy: Use cash on hand and access to capital to acquire assets that fit What we’re looking for… reate y reati e outlet reate y are rishna fro the oun ro e t fro the oun ro e t reate y Stu io reate y i hael St ker fro the oun ro e t fro the oun ro e t Targets range New technology Products

  15. Slide 15: Investor Relations Contact

    Investor Relations Contact Ruben Argueta Quidel Corporation O: 858.646.8023 E: rargueta@quidel.com

Quidel — Raymond James 41st Annual Institutional Investors Conference (March 2020) on 6ix